Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada issues warning over glucose monitors:

This article was originally published in Clinica

Executive Summary

Patients with kidney failure who use Baxter's peritoneal dialysis solution containing icodextrin (Extraneal) should ensure that they use glucose monitors not subject to interference from sugars that are released by the icodextrin. The result of using the wrong type of monitor is a falsely elevated glucose monitor reading, which can also mask a consequent hypoglycaemic effect, which could result in coma if, due to being masked, it is left untreated. Health Canada has advised patients who use icodextrin-containing dialysis solution to wear some form of personal identification, such as the bracelets and pendants available from MedicAlert, to help avoid the danger.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT054743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel